Advertisement

March 30, 2023

Supira Medical Names Dr. Azeem Latib as Medical Director

March 30, 2023—Supira Medical, Inc., a Shifamed portfolio company, announced that interventional cardiologist Azeem Latib, MD, has joined the company as Medical Director to advance its clinical activities and prepare the company for significant clinical and regulatory milestones.

The company noted that Dr. Latib played a key role throughout the development of Supira's next-generation percutaneous ventricular assist device (pVAD), a low-profile, high-continuous flow system that is designed to support cardiovascular hemodynamics for both high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients. He served as a clinical advisor and attended the initial first-in-human cases with the pVAD system, which were announced in September 2022.

Dr. Latib will retain his current position as the Section Head of Interventional Cardiology and Director of Structural Heart Interventions at Montefiore Health Systems in New York, New York.

According to Supira Medical, Dr. Latib’s professional expertise focuses on complex coronary interventions and structural heart disease, as well as new device innovation. He is a member of several professional organizations including the American College of Cardiology and the European Society of Cardiology.

He has authored more than 700 peer-reviewed articles and serves on the editorial boards for several publications including the Journal of the American College of Cardiology, Cardiovascular Revascularization Medicine, EuroIntervention, and Cardiac Interventions Today.

Dr. Latib currently serves as Chief Medical Editor of Cardiac Interventions Today.

In the company’s press release, Dr. Latib commented, “I am very excited to join the Supira team and believe it has an excellent offering with one system designed to support cardiovascular hemodynamics for both HRPCI and CS patients. The unique pump is designed to achieve the required high continuous flow without the risk of bleeding often associated with these types of devices. This will advance clinical practice and enable more physicians to confidently perform these procedures.”

Advertisement


April 3, 2023

CSI’s Diamondback 360 Orbital Atherectomy System Evaluated in ECLIPSE Trial

March 30, 2023

Abbott’s Epic Max Stented Tissue Surgical Valve Approved by FDA


)